Gene therapies, which aim to treat diseases by manipulating genes, offer promise in curing hard-to treat disease, but they’re expensive, some costing millions of dollars.
Under Cigna’s plan, members will have no out-of-pocket payments related to the cost of medicine.
The first two gene therapies to be included in Cigna’s program are Luxturna, a one-time $850,000 treatment for an inherited form of blindness, and Zolgensma, a one-time $2.1 million treatment for spinal muscular atrophy.
Additional therapies may be added to the program later, the insurer said.
Cigna plans to use the expertise of its pharmacy benefit manager Express Scripts, which it bought for $54 billion last year, and its specialty pharmacy arm, Accredo.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
